ATL1102 is an antisense oligonucleotide designed to inhibit CD49d expressed on T cells implicated in the inflammatory/immune response in Duchenne. Inhibition of CD49d aims to decrease the inflammation that accompanies loss of dystrophin in Duchenne.
A Phase 2A trial is complete.
This program is sponsored by Antisense Therapeutics.
Antisense Therapeutics at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library